Cargando…
Degradation of skeletal mass in locally advanced oesophageal cancer between initial diagnosis and recurrence
BACKGROUND: The prognostic value of a low skeletal mass index (SMI) has been investigated in locally advanced oesophageal (LAE) cancer at diagnosis. However, nothing is known about its evolution and clinical impact between initial diagnosis and recurrence. METHODS: A total of 89 patients treated for...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8653570/ https://www.ncbi.nlm.nih.gov/pubmed/34876055 http://dx.doi.org/10.1186/s12885-021-09037-3 |
_version_ | 1784611692358926336 |
---|---|
author | Zouhry, Yacine Taibi, Abdelkader Durand-Fontanier, Sylvaine Darbas, Tiffany Forestier, Geraud Monteil, Jacques Lebrun-Ly, Valérie Fayemendy, Philippe Leobon, Sophie Jesus, Pierre Deluche, Elise |
author_facet | Zouhry, Yacine Taibi, Abdelkader Durand-Fontanier, Sylvaine Darbas, Tiffany Forestier, Geraud Monteil, Jacques Lebrun-Ly, Valérie Fayemendy, Philippe Leobon, Sophie Jesus, Pierre Deluche, Elise |
author_sort | Zouhry, Yacine |
collection | PubMed |
description | BACKGROUND: The prognostic value of a low skeletal mass index (SMI) has been investigated in locally advanced oesophageal (LAE) cancer at diagnosis. However, nothing is known about its evolution and clinical impact between initial diagnosis and recurrence. METHODS: A total of 89 patients treated for LAE cancer between January 2009 and December 2019 were included in this study. Computed tomography (CT) scans before treatment and at recurrence were evaluated. SMI and other body composition parameters were analysed by the L3 scan method. RESULTS: Participants were aged 66.0 (36.0–86) years. The incidence of low SMI increased by 12.3% between diagnosis and recurrence (70.7% vs. 83.0%, respectively) over a median follow-up of 16.9 (1.7–101.6) months. Patients with high SMI at diagnosis showed loss of muscle mass (58.0 vs. 55.2 cm(2)/m(2), respectively; P < 0.001) and decreased body mass index (BMI) (27.9 vs. 26.3 kg/m(2), respectively; P = 0.05), but fat mass was increased (68.9 vs. 72.0 cm(2)/m(2), respectively; P = 0.01). Patients with low SMI at diagnosis showed no significant changes in body composition parameters and no improvement of SMI, even with nutritional support. Low SMI (hazard ratio [HR]: 1.8; 95% confidence interval [CI]: 1.02–3.16) was an independent predictor (P = 0.041) of high nutritional risk index (HR: 1.79; 95% CI: 1.03–3.11; P = 0.039) at diagnosis. CONCLUSIONS: The percentage of patients with a low SMI increased during follow-up. Our data suggest that an assessment of skeletal muscle parameters and nutrition support may be more useful in patients with a high SMI. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-09037-3. |
format | Online Article Text |
id | pubmed-8653570 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-86535702021-12-08 Degradation of skeletal mass in locally advanced oesophageal cancer between initial diagnosis and recurrence Zouhry, Yacine Taibi, Abdelkader Durand-Fontanier, Sylvaine Darbas, Tiffany Forestier, Geraud Monteil, Jacques Lebrun-Ly, Valérie Fayemendy, Philippe Leobon, Sophie Jesus, Pierre Deluche, Elise BMC Cancer Research BACKGROUND: The prognostic value of a low skeletal mass index (SMI) has been investigated in locally advanced oesophageal (LAE) cancer at diagnosis. However, nothing is known about its evolution and clinical impact between initial diagnosis and recurrence. METHODS: A total of 89 patients treated for LAE cancer between January 2009 and December 2019 were included in this study. Computed tomography (CT) scans before treatment and at recurrence were evaluated. SMI and other body composition parameters were analysed by the L3 scan method. RESULTS: Participants were aged 66.0 (36.0–86) years. The incidence of low SMI increased by 12.3% between diagnosis and recurrence (70.7% vs. 83.0%, respectively) over a median follow-up of 16.9 (1.7–101.6) months. Patients with high SMI at diagnosis showed loss of muscle mass (58.0 vs. 55.2 cm(2)/m(2), respectively; P < 0.001) and decreased body mass index (BMI) (27.9 vs. 26.3 kg/m(2), respectively; P = 0.05), but fat mass was increased (68.9 vs. 72.0 cm(2)/m(2), respectively; P = 0.01). Patients with low SMI at diagnosis showed no significant changes in body composition parameters and no improvement of SMI, even with nutritional support. Low SMI (hazard ratio [HR]: 1.8; 95% confidence interval [CI]: 1.02–3.16) was an independent predictor (P = 0.041) of high nutritional risk index (HR: 1.79; 95% CI: 1.03–3.11; P = 0.039) at diagnosis. CONCLUSIONS: The percentage of patients with a low SMI increased during follow-up. Our data suggest that an assessment of skeletal muscle parameters and nutrition support may be more useful in patients with a high SMI. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-09037-3. BioMed Central 2021-12-07 /pmc/articles/PMC8653570/ /pubmed/34876055 http://dx.doi.org/10.1186/s12885-021-09037-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Zouhry, Yacine Taibi, Abdelkader Durand-Fontanier, Sylvaine Darbas, Tiffany Forestier, Geraud Monteil, Jacques Lebrun-Ly, Valérie Fayemendy, Philippe Leobon, Sophie Jesus, Pierre Deluche, Elise Degradation of skeletal mass in locally advanced oesophageal cancer between initial diagnosis and recurrence |
title | Degradation of skeletal mass in locally advanced oesophageal cancer between initial diagnosis and recurrence |
title_full | Degradation of skeletal mass in locally advanced oesophageal cancer between initial diagnosis and recurrence |
title_fullStr | Degradation of skeletal mass in locally advanced oesophageal cancer between initial diagnosis and recurrence |
title_full_unstemmed | Degradation of skeletal mass in locally advanced oesophageal cancer between initial diagnosis and recurrence |
title_short | Degradation of skeletal mass in locally advanced oesophageal cancer between initial diagnosis and recurrence |
title_sort | degradation of skeletal mass in locally advanced oesophageal cancer between initial diagnosis and recurrence |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8653570/ https://www.ncbi.nlm.nih.gov/pubmed/34876055 http://dx.doi.org/10.1186/s12885-021-09037-3 |
work_keys_str_mv | AT zouhryyacine degradationofskeletalmassinlocallyadvancedoesophagealcancerbetweeninitialdiagnosisandrecurrence AT taibiabdelkader degradationofskeletalmassinlocallyadvancedoesophagealcancerbetweeninitialdiagnosisandrecurrence AT durandfontaniersylvaine degradationofskeletalmassinlocallyadvancedoesophagealcancerbetweeninitialdiagnosisandrecurrence AT darbastiffany degradationofskeletalmassinlocallyadvancedoesophagealcancerbetweeninitialdiagnosisandrecurrence AT forestiergeraud degradationofskeletalmassinlocallyadvancedoesophagealcancerbetweeninitialdiagnosisandrecurrence AT monteiljacques degradationofskeletalmassinlocallyadvancedoesophagealcancerbetweeninitialdiagnosisandrecurrence AT lebrunlyvalerie degradationofskeletalmassinlocallyadvancedoesophagealcancerbetweeninitialdiagnosisandrecurrence AT fayemendyphilippe degradationofskeletalmassinlocallyadvancedoesophagealcancerbetweeninitialdiagnosisandrecurrence AT leobonsophie degradationofskeletalmassinlocallyadvancedoesophagealcancerbetweeninitialdiagnosisandrecurrence AT jesuspierre degradationofskeletalmassinlocallyadvancedoesophagealcancerbetweeninitialdiagnosisandrecurrence AT delucheelise degradationofskeletalmassinlocallyadvancedoesophagealcancerbetweeninitialdiagnosisandrecurrence |